会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Mesogenic stabilizers
    • 介晶稳定剂
    • US08623238B2
    • 2014-01-07
    • US13204861
    • 2011-08-08
    • Ruisong XuXiao-Man DaiAnil KumarMeng HeChenguang LiRachael L. Yoest
    • Ruisong XuXiao-Man DaiAnil KumarMeng HeChenguang LiRachael L. Yoest
    • C09K19/52C09K19/06C09K19/34C09K19/32C09K19/00C09K19/08C07D211/00C07C69/76C07D315/00
    • C09K19/3483C07D211/46C09K19/54C09K2019/0448
    • The present invention relates to compounds represented by the following Formula Ic, in which R2-R6 can each independently be selected from hydrogen or hydrocarbyl (e.g., methyl); L1 and L4 are each independently a divalent linking group, such as a bond or —OC(O)—R8—C(O)O—, where R8 can be divalent hydrocarbyl (e.g., —CH2CH2—); each L2 and each L5 each independently represent a flexible segment, such as divalent linear or branched C1-C25 alkyl; each L3 and each L6 each independently represent a rigid segment including, for example, optionally substituted phenylen-1,4-diyl groups; t and s are each independently from 1 to 4; m and p are each independently from 0 to 4 for each t, provided that the sum of m and p is at least 1 for each t; q and r are each independently from 0 to 4 for each s, provided that the sum of q and r is at least 1 for each s; and E1 and E2 can each independently be hydrogen or hydrocarbyl. The present invention also relates to compositions, such as liquid crystal compositions, and articles, such as optical elements, that include the compound represented by Formula Ic.
    • 本发明涉及由下式Ic表示的化合物,其中R 2 -R 6各自独立地选自氢或烃基(例如甲基); L 1和L 4各自独立地是二价连接基团,例如键或-OC(O)-R 8 -C(O)O-,其中R 8可以是二价烃基(例如-CH 2 CH 2 - )。 每个L 2和每个L 5各自独立地表示柔性链段,例如二价直链或支链C 1 -C 25烷基; 每个L3和每个L6各自独立地表示包括例如任选取代的苯基-1,4-二基的刚性链段; t和s各自独立地为1至4; 对于每个t,m和p各自独立地为0至4,条件是对于每个t,m和p之和至少为1; q和r各自各自为0至4,条件是每个s的q和r之和至少为1; E1和E2各自独立地为氢或烃基。 本发明还涉及包含式Ic表示的化合物的组合物,例如液晶组合物和诸如光学元件的制品。
    • 8. 发明授权
    • Isoxazol-3(2H)-one analogs as therapeutic agents
    • 异恶唑-3(2H) - 酮类似物作为治疗剂
    • US08415378B2
    • 2013-04-09
    • US12755010
    • 2010-04-06
    • Jonas BoströmLeifeng ChengTomas FexMichael KarleDaniel PettersenPeter Schell
    • Jonas BoströmLeifeng ChengTomas FexMichael KarleDaniel PettersenPeter Schell
    • A01N43/40A01N43/80A61K31/445A61K31/42C07D401/00C07D405/00C07D409/00C07D411/00C07D413/00C07D417/00C07D419/00C07D421/00C07D261/00C07D307/02C07D315/00C07D407/00
    • C07D413/04
    • or a pharmaceutically suitable salt thereof, wherein, R1 and R2 independently are hydrogen, deuterium, aryl, hetero aryl, C1-C8 alkyl, optionally being substituted with one or more substituents independently being R3, R3 is an aryl, hetero aryl, fluorine(s), a C1-C6 alkyl containing one or more fluorine, a C1-C6 alkyl containing one or more deuterium, a C1-C6 alkyl containing hydroxy, the aryl and heteroaryl optionally being substituted with one or more halogen, a fluorinated alkoxy, a fluorinated alkyl, a sulfonyl, one or more deuterium, a C1-6 alkyl, a C1-6 alkoxy, a nitrile, or R3 is a C1-6 alkyl optionally substituted with one or more of the following groups: COOR4, OCOR4, CONR5R6, NR5COR6, OR4; wherein, R4 is a C1-10 alkyl optionally substituted with one or more fluorine, deuterium, alkoxy, arylcarboxylate, alkyl carboxylate; R5 and R6 are independently selected from hydrogen, alkyl or they may together form a 4-8 membered carbon ring; or R1 and R2 form a 3-10 membered carbon ring optionally comprising O or N and optionally substituted with a C1-10 alkyl or aryl, hetero aryl optionally substituted with R3.
    • 或其药学上合适的盐,其中R 1和R 2独立地是氢,氘,芳基,杂芳基,任选被一个或多个取代基独立地被R 3取代的C 1 -C 8烷基,R 3是芳基,杂芳基,氟( 含有一个或多个氟的C 1 -C 6烷基,含有一个或多个氘的C 1 -C 6烷基,含羟基的C 1 -C 6烷基,任选被一个或多个卤素取代的芳基和杂芳基,氟化烷氧基, 氟化烷基,磺酰基,一个或多个氘,C 1-6烷基,C 1-6烷氧基,腈或R 3是任选被一个或多个下列基团取代的C 1-6烷基:COOR 4,OCOR 4, CONR5R6,NR5COR6,OR4; 其中,R4为任选被一个或多个氟,氘,烷氧基,芳基羧酸酯,羧酸烷基酯取代的C 1-10烷基; R 5和R 6独立地选自氢,烷基或它们可以一起形成4-8元碳环; 或R 1和R 2形成任选地包含O或N并任选被C 1-10烷基或芳基取代的3-10元碳环,任选被R 3取代的杂芳基。